download biotech19jan

7/30/2019 Download Biotech19jan

1/30

March, 2005

Unprecedented GrowthOpportunity

BIOTECHNOLOGY


2/30

March, 2005

Biotechnology

India - An Overview

Market and Growth Potential

Players

Opportunities

Why India?

Contact in India


3/30

March, 2005

India - An Introduction

Population

States/UTs

Geographical Area

Languages recognised

Business language

Per Capita Income**

GDP**

Over 1 bn

35

3.3 mn sq kms

22

English

US$ 534

US$ 650 bn

**(at factor cost & at current prices)

1USD=43.54 INR (as on July 4, 2005)

Source:CSO Statistics


4/30

March, 2005

India - Fast pace Growth

Largest democracy

4th largest economy by PPP index

6th largest energy consumer

ForEx reserves skyrocket from US$ 42 bn (2001) to

US$ 133 bn (February, 2005)

GDP growth to continue between 6-8%

3rd largest economy by 2050: Goldman Sachs

Leading in IT & BPO

Oil & Gas and Biotechnology sunrise industries


5/30

March, 2005

India - Leading the world

Hero Honda - largest manufacturer of motorcycles

Moser Baer- among the top three media manufacturers

in the world

Pharmaceutical Industry - 4th largest in world

Walmart, GAP, Hilfigersources more than

USD 1bn worth apparel from India

100 Fortune 500 have set R&D facilities in India

including GE, Delphi, Eli Lilly, HP, Heinz and Daimler

Chrysler


6/30

March, 2005

Biotechnology

India - An Overview


Players

Opportunities

Why India?

Contact in India


7/30March, 2005

Biotech Market - Dynamic and growing

Size (2004-05) US$ 1090.5 mn

Largest segment Biopharma

Revenue from exports (2003-04) 56%

Total investment (2003-04) US$ 137 millionRate of growth over 202-2003 26%


8/30March, 2005

Bio Agri6.95%

Bio Pharma75.24 %

Bio Services8.95%

Bio-IT2.09 %

Biopharma leads the way

Composition of Indian Biotech Sector (2004-05)

BioIndustrial6.74%

Source:Biospectrum-ABLE Survey


9/30March, 2005

Market - A consistent uptrend

2002-03

2010

25% growth in investment

70% growth in employment

74% growth in R&Dmanpower

10% of global industry

1 million skilled jobs

US$ 5 billion annual

revenues

Source: Confederation of Indian Industry (CII)


10/30

March, 2005

Biotechnology

India - An Overview


Players

Opportunities

Why India?

Contact in India


11/30

March, 2005

Indian Players


12/30

March, 2005

MNCs Scripting Success in India


13/30

March, 2005

Biotechnology

India - An Overview


Players

Opportunities

Why India?

Contact in India


14/30

March, 2005

Year US$ million

Growth

(%)

2000-01 54

2001-02 108.9 102

2002-03 137.2 26

Investments

Annual investments in this sector will be of the order of US$ 150mn and are growing at the rate of 25%.

An additional investment of US$ 216 mn is

expected in FY2005


15/30

March, 2005

Vaccine Sales of US$ 383.6 mn (2004-05)

Therapeutic Marketing licenses granted forover 25 recombinant therapeuticproteins

Diagnostics Sales market - US$ 138.2 mn (2004-05)

Invest in Biopharmaceuticals


16/30

March, 2005

India: The Vaccine Hub

Indian firms estimated to supply 90% of globaldemand for the measles vaccine, in the nearfuture.

Serum Institute, Pune is believed to be theworld`s largest manufacturer of DPT vaccines.

Indian Immunologicals operates the world`ssecond largest plant for veterinary vaccines andis also the world`s largest manufacturer of thevaccine against Foot and Mouth Disease.


17/30

March, 2005

Invest in Biopharmaceuticals

Therapeutic Accounts for 16.7% of total biopharmasales

Diagnostics Forecast to grow by 35-40% in 2005Immuno diagnostic market to increase4 to 5 folds by 2005


18/30

March, 2005

Invest in Bioinformatics

By 2006 bionformatics market to grow

2004-05 US$ 22.9 mn

By 2006 US$ 120 mn

Source: International Data Corporation (IDC)

Opportunities for

investment

Data mining

Gene annotation

Software bioinformatics

interface development


19/30

March, 2005

Genomics

Industrial Biotech

Invest in Genomics and Industrial Biotech

Size (2004-05) US$ 73.5 mn


20/30

March, 2005

Invest in Agri Biotech

Biofertilisers

GM Crops and seeds Biopesticides

Biofuels


21/30

March, 2005

Invest in Agri Biotech

Biofertilisers

GM Crops and seeds Biopesticides

Biofuels


22/30

March, 2005

Quality

Speed

Technology

Disease Profile

Investigators

Genetic diversity

Ethics

Quality guidelines conformed

Patient enrolment rates upto six times

higher than US

CROs to benefit from Indias IT

strengths in data management

High incidence of infectious/lifestyle

diseases

Excellent pool of qualified & trained

doctors and physicians

Clinical Trials - Destination India


23/30

March, 2005

Biotechnology

India - An Overview


Players

Opportunities

Why India?

Contact in India


24/30

March, 2005

The India Advantage

Trained manpowerand knowledge base

Rich biodiversity Extensive clinical trialsopportunities

Excellent networkof research laboratories

Well-developedbase industries


25/30

March, 2005

40 National ResearchInstitutes

300 life sciencescolleges

120 medical colleges

200 biotech companies

100 teaching hospitals

The Infrastructure Advantage

15,000 scientists

500,000 graduatesper annum

17,500 medical graduatesper annum

Employing 25,000scientists in R&D

Employing medical &paramedical professionals

&


26/30

March, 2005

The R & D Advantage

Genetic Engineering

DNA technologies

New Drug Delivery Systems

Rational drug design

Stem cell research

Bioinformatics

Biotech

R&D

strengthsspread

across

range of

segments


27/30

March, 2005

The Policy Advantage

India has transitioned from a process patent regime to a

product patent regime w.e.f January, 2005

150% weighted deduction on R&D expenditure

Single window application processing proposed by DBT

New biotech proposals to be cleared within 150 days

Formation of a SME Growth Fund to provide equity support

to small & medium units in the biotechnology sectors (Union

Budget 2005-06)


28/30

March, 2005

Union Budget 2005-06

Benefits enjoyed by Export Oriented Units (EOU) extended

to Biotech Parks

- 100% FDI permitted through automatic route

- BTP units exempt from payment of Income Tax

- Export proceeds to be realised within 12 months

- BTPs allowed to retain 100% export earnings in the EEFC

account

The Biotech Park Advantage


29/30

March, 2005

Biotechnology

India - An Overview


Players

Opportunities

Why India?

Contact in India

C


30/30

March 2005

Contact in India

Confederation of Indian Industry (CII)

The Mantosh Sodhi Centre23 Institutional Area

Lodi RoadNew Delhi 110003

Tel 0091 11 24629994 - 7

Fax 0091 11 24626149/24615693E-mail [email protected]

download biotech19jan

Documents